Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting

Thomas Niel, The Motley Fool

Wed, August 26, 2026 at 4:50 PM GMT+3 3 min read

• GILD +0.52%
• NVDA +8.74%

After months of sideways price action, Gilead Sciences (NASDAQ: GILD) has started zooming higher. This comes on the heels of the pharmaceutical company's latest quarterly earnings release.

Trading around $130 per share ahead of earnings, the stock has since surged to around $146 per share. Further upside may be in the cards, mostly due to the key factor driving its post-earnings rally.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

HIV drug portfolio sends Gilead soaring

Gilead released its Q2 2026 results on Aug. 4. Admittedly, the earnings release was mixed at best. The biotech reported $7.8 billion in sales, up 10% year over year and ahead of forecasts . The company also recorded a net loss of $8.45 per share.

However, this figure was mainly due to significant in-process R&D charges related to the company's recent acquisition of several biotech companies, including Arcellx. These charges may hurt the bottom line today but could pay off if Gilead's ongoing oncology pivot proves successful.

Based on the stock's post-earnings rally, investors clearly forgave management for the losses, focusing mostly on the key positive with Gilead's latest results: continued success with its HIV drug portfolio. While flagship treatment Biktarvy keeps steadily growing in sales, the main milestone is with Gilead's portfolio of PrEP (HIV prevention) medicines, which hit over $1 billion in quarterly sales for the first time.

The post-earnings takeaway for investors

HIV product sales alone grew 12% during Q2 2026, with Descovy sales rising 48% and twice-yearly HIV prevention injection Yeztugo rising from just $15 million to $232 million. Better yet, management anticipates continued growth in the HIV drugs segment, including the prospect of Yeztugo reaching blockbuster status, with annual sales over $1 billion.

This, coupled with diversification efforts, points to strong results moving forward. Forecasts already call for Gilead's 2027 earnings to come in between $9.19 and $11.10 per share. This means Gilead could be trading for between 13 and 16 times forward earnings. With established biotech stocks like Amgen trading for nearly 20 times forward earnings, the potential runway for Gilead could prove substantial.

Should you buy stock in Gilead Sciences right now?

Before you buy stock in Gilead Sciences, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $443,461!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,307,633!*

That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of August 26, 2026.

Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Gilead Sciences. The Motley Fool has a disclosure policy.

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting was originally published by The Motley Fool